{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:54:39Z","timestamp":1790646879446,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"ESMO Translational Research Programme"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ejca.2015.05.018","type":"journal-article","created":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T12:15:32Z","timestamp":1433765732000},"page":"1694-1703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease"],"prefix":"10.1016","volume":"51","author":[{"given":"Angela","family":"Lamarca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Benafif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2015.05.018_b0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0010","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2015.05.018_b0015","unstructured":"Cancer Survival Trends in England and Wales 1971\u20131995: deprivation and NHS region."},{"key":"10.1016\/j.ejca.2015.05.018_b0020","unstructured":"AJCC Cancer Staging Manual, 7th ed., in, 2010."},{"key":"10.1016\/j.ejca.2015.05.018_b0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1023\/A:1008241008379","article-title":"Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin","volume":"9","author":"Ducreux","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0035","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/0959-8049(95)00323-B","article-title":"Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours","volume":"31A","author":"Ellis","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.21621","article-title":"Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma","volume":"106","author":"Park","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0045","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/sj.bjc.6602576","article-title":"Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer","volume":"92","author":"Rao","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0055","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.1996.14.8.2311","article-title":"Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer","volume":"14","author":"Patt","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00000421-200008000-00023","article-title":"Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas","volume":"23","author":"Choi","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0065","first-page":"3375","article-title":"Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer","volume":"7","author":"Patt","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2015.05.018_b0070","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/annonc\/mdh096","article-title":"Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial","volume":"15","author":"Kornek","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0075","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2001.19.20.4089","article-title":"Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study","volume":"19","author":"Gebbia","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0080","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/cncr.22902","article-title":"Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer","volume":"110","author":"Riechelmann","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0085","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/sj.bjc.6605377","article-title":"Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials","volume":"101","author":"Wagner","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0090","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/cncr.24970","article-title":"The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma","volume":"116","author":"Cereda","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0095","first-page":"23","article-title":"Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report","volume":"17","author":"Bhargava","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ejca.2015.05.018_b0100","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andre","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0105","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study","volume":"28","author":"Sharma","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0110","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2015.05.018_b0115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0120","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/B:DRUG.0000011797.09549.53","article-title":"Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer","volume":"22","author":"Tsavaris","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2015.05.018_b0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/archsurg.1991.01410270099016","article-title":"Radical resection for carcinoma of the ampulla of Vater","volume":"126","author":"Monson","year":"1991","journal-title":"Arch Surg"},{"key":"10.1016\/j.ejca.2015.05.018_b0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000658-199610000-00005","article-title":"Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors","volume":"224","author":"Nakeeb","year":"1996","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2015.05.018_b0140","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejso.2011.03.135","article-title":"Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group","volume":"37","author":"Regimbeau","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0145","unstructured":"National Comprehensive Cancer Network (NCCN) guidelines. Available at: <www.nccn.org> [accessed 04.11.14]."},{"key":"10.1016\/j.ejca.2015.05.018_b0150","unstructured":"<http:\/\/pi.lilly.com\/us\/gemzar.pdf> [accessed 04.11.14]."},{"key":"10.1016\/j.ejca.2015.05.018_b0155","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2000.18.14.2780","article-title":"Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and Leukemia Group B 9565","volume":"18","author":"Venook","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0160","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000096249","article-title":"Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study","volume":"70","author":"Androulakis","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2015.05.018_b0165","article-title":"FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer","author":"Novarino","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.05.018_b0170","doi-asserted-by":"crossref","unstructured":"Mane J, et al. Second-line chemotherapy with capecitabine (CAP) and oxaliplatin (OX) in patients with pancreatic or biliary tree adenocarcinoma (ADC). J Clin Oncol 29:2011 (suppl 4; abstr 308), 2013.","DOI":"10.1200\/jco.2011.29.4_suppl.308"},{"key":"10.1016\/j.ejca.2015.05.018_b0175","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/CAD.0b013e3283017f94","article-title":"Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent\/metastatic biliary tract carcinoma","volume":"19","author":"Lim","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2015.05.018_b0180","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/sj.bjc.6600543","article-title":"Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial","volume":"87","author":"Nehls","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2015.05.018_b0185","unstructured":"<http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf> [accessed 04.11.14]."},{"key":"10.1016\/j.ejca.2015.05.018_b0190","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1016\/j.ejca.2015.05.018_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.fl.25.010193.000245","article-title":"The history of Poiseuiller\u2019s law","volume":"1993","author":"Sutera","year":"1993","journal-title":"Annu Rev Fluid Mech"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915004499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915004499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T11:42:27Z","timestamp":1717933347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915004499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":39,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0959804915004499"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.05.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}